|Bid||18.29 x 2200|
|Ask||18.30 x 1400|
|Day's Range||18.01 - 18.38|
|52 Week Range||16.10 - 21.61|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||22.50|
|Forward Dividend & Yield||0.83 (4.36%)|
|Ex-Dividend Date||Sep 26, 2019|
|1y Target Est||2,482.30|
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s supplemental New Drug Application (sNDA) to expand the use of ALUNBRIG (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ALUNBRIG is a next-generation tyrosine kinase inhibitor (TKI) that was designed to target and inhibit ALK genetic alterations.
Walmart Inc might finally have found the sweet spot in Japan's food market with a fast-growing venture ranked third in a nascent online grocery sector, as the brick-and-mortar stores it bought into two decades ago continue their search for profit. The barely year-old tie-up between the U.S. supermarket chain's Seiyu and local e-commerce firm Rakuten Inc clocked 30% sales growth for late October through December versus the same period a year earlier when Seiyu was going it alone, said Rakuten Seiyu NetSuper Chief Executive Tamae Takeda.
New vedolizumab (Entyvio) data from the VISIBLE 2 trial presented at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO)
LogicBio Therapeutics had hoped to begin testing what could be the first gene-targeting treatment designed specifically for infants and children, but FDA qualms have put a moratorium on those plans.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will feature 11 presentations, including 10 posters, and one oral presentation highlighting its ongoing studies and commitment to rare lysosomal storage disorders at the 16th annual WORLDSymposium™ 2020 in Orlando, Florida, February 10-13. Presentations and other company activities will focus on Takeda's continued research and development efforts in lysosomal storage disorders (LSDs) including Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II), type 1 Gaucher disease, Fabry disease and metachromatic leukodystrophy (also known as MLD).
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
Takeda Pharmaceutical Co Ltd expects to make an operating profit this fiscal year, compared with its previous forecast for a loss, thanks to sales growth in its core brands and savings from its purchase of Shire Plc, it said on Tuesday. Japan's largest drugmaker expects an operating profit of 10 billion yen ($92 million) for the year ending in March, versus its previous estimate for a loss of 110 billion yen, it said alongside its third-quarter results. "The way business is progressing, the way we are delivering our synergies and managing our margin is very encouraging for next year," Takeda CEO Christophe Weber said on conference call.
Takeda Pharmaceutical Co Ltd said it now expects an operating profit for the full year, as opposed to its earlier projection for a loss, due to stronger sales and cost savings from its integration with Shire Plc. The company forecast an operating profit of 10 billion yen ($91.91 million) for the year ending in March, versus its previous forecast for a loss of 110 billion yen. Takeda surprised markets in May last year when it reversed its full-year profit forecast to a loss, citing costs linked to its $59 billion Shire deal.
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...
Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®*
After executing one of the drug industry’s biggest acquisitions in recent years, it would be easy to assume that Takeda Pharmaceutical Co. Ltd. executives would paint the company as a frontrunner. But that’s not entirely the case.
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive year. Corporate Knights assesses more than 7,300 companies against 21 key performance indicators. It uses these indicators to determine the top 1% most sustainable companies in the world, which are announced annually at the World Economic Forum in Davos, Switzerland.
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) ("Takeda") will provide an update on the progress of its business transformation and priorities today at the 38th Annual J.P. Morgan Healthcare Conference. President and Chief Executive Officer, Christophe Weber, will share details on Takeda’s portfolio and pipeline strategy, financial outlook, and ongoing sustainability efforts, including its newly established commitment to carbon neutrality across its value chain.
Wave Life Sciences took its first steps this week after a major corporate setback, releasing early data on one of the two potential treatments for Huntington’s disease, which it's developing with Takeda Pharmaceutical Co. Ltd. The drugs are now Wave’s most advanced products in development following its decision earlier this month to halt testing on its Duchenne muscular dystrophy treatment. In an interview with the Business Journal following the news, Wave's CEO stood by the decision to start small.
Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals.